There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (NASDAQ:VRTX) and Natus Medical Inc (NASDAQ:BABY) with bullish sentiments.
Vertex Pharmaceuticals (VRTX)
Raymond James analyst Laura Chico maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $201. The company’s shares opened today at $157.
According to TipRanks.com, Chico is a 1-star analyst with an average return of -2.2% and a 44.7% success rate. Chico covers the Healthcare sector, focusing on stocks such as Dova Pharmaceuticals Inc, Paratek Pharmaceuticals, and Acer Therapeutics Inc.
Currently, the analyst consensus on Vertex Pharmaceuticals is a Strong Buy with an average price target of $195.91, which is a 24.8% upside from current levels. In a report issued on October 11, Jefferies also maintained a Buy rating on the stock with a $210 price target.
.
See today’s analyst top recommended stocks >>
Natus Medical Inc (BABY)
In a report released today, David Solomon from Roth Capital maintained a Buy rating on Natus Medical Inc, with a price target of $36. The company’s shares opened today at $29.06, close to its 52-week low of $28.
According to TipRanks.com, Solomon is a 1-star analyst with an average return of -7.0% and a 20.0% success rate. Solomon covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Apollo Endosurgery Inc, and BioNano Genomics Inc.
Natus Medical Inc has an analyst consensus of Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
